A Safety, Tolerability And Efficacy Study Of Nc410 Plus Pembrolizumab In Participants With Advanced Unresectable Or Metastatic Solid Tumors
Posted Date: Apr 26, 2024
- Investigator: Davendra Sohal
- Specialties: Cancer, Cervical Cancer, Head and Neck Cancer, Lung Cancer
- Type of Study: Drug
This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab. This study will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or metastatic ICI refractory solid tumors OR ICI naïve MSS/MSI-low solid tumors
Criteria:
Null
Keywords:
Solid Tumors, Endometrial Cancer
For More Information:
Kayla Webb
NULL
cancer@uchealth.com